Chen-Yen Lin, Ph.D.
Affiliations: | 2012 | Statistics | North Carolina State University, Raleigh, NC |
Area:
StatisticsGoogle:
"Chen-Yen Lin"Parents
Sign in to add mentorHoward D. Bondell | grad student | 2012 | NCSU | |
(Some Recent Developments in Parametric and Nonparametric Regression Models.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Rich P, Goldblum O, Disch D, et al. (2020) Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis. Journal of Drugs in Dermatology : Jdd. 19: 741-746 |
Murage MJ, Gilligan AM, Tran O, et al. (2019) Ixekizumab Treatment Patterns and Healthcare Utilization and Costs for Patients with Psoriasis. The Journal of Dermatological Treatment. 1-26 |
Langley RGB, Reich K, Strand V, et al. (2019) Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation |
Tony H, Galindez E, Sprabery AT, et al. (2019) Sat0396 Improvement In The Signs And Symptoms Of Psoriatic Arthritis With Ixekizumab Compared To Placebo In Patient Subgroups Defined By Baseline Disease Characteristics Annals of the Rheumatic Diseases |
Kirkham LB, Sesin C, Sprabery AT, et al. (2019) Op0110 Ixekizumab Improves Signs And Symptoms Of Psoriatic Arthritis In Patients Who Have Had Inadequate Response To 1 Or 2 Tumor Necrosis Factor Inhibitors Annals of the Rheumatic Diseases. 78: 128-129 |
Combe B, Tsai T, Odhav S, et al. (2019) Sat0374 ixekizumab, with or without concomitant methotrexate, improves the signs and symptoms of psa for up to 52 weeks of treatment Annals of the Rheumatic Diseases. 78: 1270-1271 |
Gottlieb AB, Strand V, Kishimoto M, et al. (2018) Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology (Oxford, England) |
Wu JJ, Lin C, Sun L, et al. (2018) Minimal Clinically Important Difference (MCID) for Work Productivity and Activity Impairment (WPAI) Questionnaire in Psoriasis Patients. Journal of the European Academy of Dermatology and Venereology : Jeadv |
Cather J, Meeuwis K, Burge R, et al. (2018) Ixekizumab provides greater improvement versus placebo on the impact of genital psoriasis on sexual activity for patients with moderate-to-severe genital psoriasis in a randomized double-blind phase 3b clinical trial Journal of the American Academy of Dermatology. 79 |
Kimball AB, Luger T, Gottlieb A, et al. (2017) Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results From a Phase III Clinical Trial and Long-term Extension. Acta Dermato-Venereologica |